Curanex Pharmaceuticals Inc (CURX) — RQD Stock Rating Cockpit

Per the Roarable RQD rating, CURX scores 34 out of 100, earning a letter grade of E and the verdict "Roarable Strong Sell — Forensic Risk / Avoid." The five pillars are: Fundamental Cash Engine at 5/20 (ROIC of -35%; FCF yield of 0%); Whale 13F Flow at 6/20 (institutional accumulation and options positioning); Insider Conviction at 5/20 (SEC Form 4 and Congressional PTR cluster flow); Macro Regime Fit at 8/20 (Beta 1.0; sector sensitivity); and Forensic Balance Sheet at 10/20 (Altman Z 2.5; Piotroski F 1/9; Debt/Equity 0.5).

Read together, the weakest pillars are the cash-generation engine and insider conviction, both at 5/20. A 0% FCF yield and -35% ROIC indicate the company is not currently converting capital into cash returns, which is the central valuation tradeoff: the stock's price of $4.94 is not supported by reported cash earnings on the data provided. The forensic balance sheet scores highest at 10/20, but a Piotroski F-Score of 1/9 is weak and signals limited financial strength across the standard checks. The macro pillar's 8/20 reflects a Beta of 1.0, which means market-level sensitivity without a clear defensive offset. For a prospective investor, the RQD framework points to elevated downside and forensic risk; any upside thesis would depend on operational or catalyst developments not captured in the current source data.

Curanex Pharmaceuticals Inc (CURX) is a NASDAQ-listed issuer in the Health Care sector, within the Biotechnology: Pharmaceutical Preparations industry, per the profile. The source data does not describe its specific products, customers, or revenue model. Reported revenue in the SEC financials is $0.0M for both FY 2025 and FY 2024, so the source data does not show a revenue-generating operating business during these periods.

Per the SEC financials, the company reported operating and net losses of $-4.2M in FY 2025 and $-0.4M in FY 2024, with free cash flow of $-10.5M and $-0.6M respectively. Per the market data, gross, operating, and net margins are each 0%, and ROIC is -35%. Per the Roarable RQD rating, the Altman Z-Score is 2.5 and the Piotroski F-Score is 1/9, with Debt/Equity of 0.5. Cash of $5.0M is reported for FY 2025, while debt is listed as N/A in the SEC financials.

Recent news items in the source data are generic market-wire headlines, each tagged with a YELLOW light and "MARKET WIRE" impact label. They include a TradingView estimates report, a Yahoo! Finance Canada seasonal returns item (headline references a different company name, "Alps Group Inc (ALPS)"), a report of CURX slipping 0.94% to $4.76 toward lower support, an unusual-volume screen mention, and a report of CURX up +4.58% with resistance cited at $5.27. The source data does not contain substantive company-specific catalysts such as trial results, regulatory actions, or financing announcements.

Per the Butterfly Supply-Chain Graph, the proprietary signal is a LIQUIDITY_TAILWIND with a BULLISH direction, severity 94, and terminal label "MACRO TAILWIND SCORE (96/100)." The signal cites a True Net Liquidity Index of $5,745.73B with a -0.64% 4-week rate of change and High-Yield OAS of +2 bps, and assigns CURX a 5.70x Net Liquidity beta with r = -0.24. Because the regression correlation is weak (r = -0.24), the liquidity sensitivity estimate carries limited statistical confidence and should be weighed accordingly against the forensic metrics above.

Per the Butterfly Supply-Chain Graph, supply chain status is listed as NONE and no butterfly links are provided. Upstream and downstream dependencies, and specific sector correlations beyond the liquidity signal, are not available in source data. The only cross-market linkage in the data is the liquidity beta described above, which implies CURX may respond to changes in net liquidity conditions more than typical equities. Investors should monitor whether any such liquidity sensitivity persists given the weak r value, and should note that with a $7.7M market cap and 0% FCF yield, the company's capacity to absorb adverse financing conditions is not established by the source data.

• What products or therapeutic programs generate or are expected to generate revenue, given $0.0M reported revenue in both periods?
• What is the company's debt balance, since the SEC financials list debt as N/A while the Roarable RQD rating reports Debt/Equity of 0.5?
• What is the cash runway, given $5.0M in FY 2025 cash against $-10.5M in FY 2025 free cash flow?
• What drove the FY 2025 jump in operating losses from $-0.4M to $-4.2M?
• What is the source of the 52-week range ($3.58 - $14.12) and the 13F, insider, and analyst coverage gaps, and are there any pending financings or dilution events?